查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424834

基因組學市場：按技術、應用、最終用戶、服務劃分-全球預測（至2031年）

Genomics Market by Technology, Application, End User, Offering - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 320 Pages | 訂單完成後即時交付

價格

到 2031 年，全球基因組學市場預計將達到 705.2 億美元，2024 年至 2031 年複合年增長率為 11.1%。

經過廣泛的二次和初步研究以及對市場情景的詳細分析，本報告對關鍵行業驅動因素、限制因素、挑戰和機會進行了分析。 基因組學市場的成長是由遺傳患者病率上升、基因組學數據越來越多地融入臨床工作流程、增加基因組學計畫的資金和投資、擴大基因組學在醫療保健和製藥中的應用所推動的。驅動因素包括研發支出的增加、降低定序成本並增加醫療保健支出。 然而，基因組學缺乏標準化方法以及對基因組學資料安全和隱私的擔憂正在限制該市場的成長。

此外，個人化藥物和基因治療的日益普及預計將創造市場成長機會。 然而，缺乏熟練的生物資訊學和基因組學人才、基因組學技術的商業化和擴展給市場利益相關者帶來了重大挑戰。

本報告是基於對領先市場參與者在四年期間（2020-2024 年）的產品組合、區域影響力和關鍵策略發展的廣泛評估，提供了競爭格局。 全球基因組學市場的主要參與者包括安捷倫科技公司（美國）、Bio-Rad Laboratories, Inc.（美國）、丹納赫公司（美國）、賽默飛世爾科技公司（美國）、Illumina, Inc. （美國） )、QIAGEN N.V.（荷蘭）、Pacific Biosciences of California, Inc.（美國）、Oxford Nanopore Technologies Plc.（英國）、Eppendorf SE（德國）、Myriad Genetics, Inc.（美國）、Revvity, Inc. （原PerkinElmer） , Inc. 美國）和華大基因有限公司（中國）。

在本報告研究的所有產品中，消耗品領域預計在預測期內複合年增長率最高。 此細分市場複合年增長率最高的原因是遺傳疾病盛行率不斷上升、基因檢測的採用率增加以及消耗品而非設備的定期購買。 遺傳疾病的日益普及推動了對基因檢測的需求，從而推動了耗材的採用。 例如，根據美國MJH生命科學公司2022年發布的報告，全球每年約有30萬個嬰兒出生時患有鐮狀細胞疾病，全球近5%的人口受到鐮狀細胞疾病的影響。

在本報告調查的所有技術中，聚合□鍊式反應 (PCR) 領域預計將在 2024 年佔據基因組學市場的最大份額。 PCR 在臨床診斷中的使用增加、PCR 技術的進步、基因組學研究的合作研究以及 PCR 在這些研究調查中的使用是促成該細分市場最大份額的一些因素。 產品的推出進一步提高了該細分市場的重要市場份額。 例如，2023 年 3 月，Bio-Rad Laboratories 推出了 PTC Tempo 96 和 PTC Tempo Deepwell 熱循環儀，以優化定序、克隆和基因分型等 PCR 應用。

在本報告研究的所有應用中，診斷領域預計將在 2024 年佔據基因組學市場的最大份額。 基因組學在腫瘤學、新生兒篩檢和肝炎檢測中的應用佔據了這一領域的最大份額。 新生兒篩檢是對新生兒進行的測試，旨在識別已知的遺傳性疾病。 政府機構支持新生兒篩檢，透過早期發現、診斷和介入來降低新生兒遺傳疾病的發生率。 例如，2022年12月，英國政府投資超過1.106億美元（1.05億英鎊）來加速新生兒罕見疾病的診斷速度。 此類舉措在推動該細分市場的最大份額方面發揮關鍵作用。

在本報告研究的所有最終用戶中，製藥和生技公司領域預計在預測期內複合年增長率最高。 該領域複合年增長率最高的原因是製藥和生物技術公司研發的增加、研究方法中基因組學利用率的提高以及生物技術公司數量的增加。 此外，慢性病的盛行率日益增加，加速了藥物開發進程的需要，並進一步推動了製藥公司採用基因組學。

對全球基因組學市場區域狀況的詳細分析提供了五個主要區域（北美、歐洲、亞太地區、拉丁美洲、中東和非洲）的詳細定性和定量見解，並提供了關鍵國家覆蓋範圍。 到 2024 年，北美預計將佔據基因組學市場的最大份額。 北美擁有許多專門從事基因組學研究的著名研究機構、大學和組織。 由於藥物研發支出的增加和大公司的存在，該地區正在為癌症基因組學做出重大貢獻。 例如，在加拿大，製藥公司正在增加藥物發現的研發支出，從而推動了對基因組學的需求。 例如，2020 年加拿大製藥業的研發總支出預計在 18 億美元至 24 億美元之間，而 2019 年為 16 億美元至 22 億美元。 因此，研究機構的存在、遺傳疾病檢測的增加以及藥品研發支出的增加支撐著最大的區域份額。

目錄

第 1 章簡介

第 2 章研究方法

第 3 章執行摘要

第 4 章市場洞察

  • 摘要
  • 影響市場成長的因素
    • 市場動態影響分析
    • 因素分析
  • 技術趨勢
  • 基因體學市場：監理分析
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東/非洲
    • 基因治療和基因組編輯的指南和規定
  • 價格分析
  • 波特五力分析

第 5 章基因體學市場評估：依產品

  • 摘要
  • 消耗品
  • 設備
  • 軟體
  • 服務

第 6 章基因體市場評估：依技術

  • 摘要
  • 聚合□鍊式反應 (PCR)
  • 定序
    • 次世代定序 (NGS)
    • 其他定序技術
  • 核酸萃取與純化
  • 微陣列晶片
  • 其他技術

第 7 章基因體學市場評估：按應用

  • 摘要
  • 診斷
  • 藥物發現與藥物開發
  • 生命科學研究
    • 癌症研究
    • 幹細胞研究
    • 其他生命科學研究
  • 其他用途

第 8 章基因體市場評估：按最終使用者

  • 摘要
  • 製藥和生技公司
  • 醫院/診所
  • 診斷實驗室
  • CRO（藥物開發合約組織）
  • 學術/研究機構
  • 其他最終用戶

第 9 章基因體市場評估：按地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 中東/非洲

第 10 章競爭分析

  • 簡介
  • 主要成長策略
  • 競爭基準測試
  • 競爭對手儀表板
    • 行業領導者
    • 市場差異化因素
    • 領先企業
    • 新興公司
  • 市佔率分析
    • Thermo Fisher Scientific Inc.（美國）
    • Illumina, Inc.（美國）
    • Qiagen N.V.（荷蘭）

第 11 章公司簡介（公司概況、財務概況、產品組合、策略發展）

  • Thermo Fisher Scientific Inc.
  • Illumina, Inc
  • Qiagen N.V.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies plc
  • Eppendorf SE
  • Myriad Genetics, Inc.
  • Reevity, Inc.（Formerly PerkinElmer, Inc.）
  • BGI Genomics Co.,Ltd.

（註：包含前5名公司的SWOT分析）

第 12 章附錄

Product Code: MRHC - 104157

Genomics Market by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction) Application (Drug Discovery, Diagnostic, Research) End User (Pharmaceutical, Hospital, Academic) Offering (Instrument, Consumable, Software)-Global Forecast to 2031

The global genomics market is projected to reach $70.52 billion by 2031, at a CAGR of 11.1% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the genomics market is driven by the rising prevalence of genetic diseases, the increasing incorporation of genomic data in clinical workflows, increasing funding and investments in genomics projects, the growing applications of genomics in the healthcare sector, rising pharmaceutical R&D expenditures, decreasing cost of sequencing, and increasing healthcare spending. However, the lack of standardized approaches in genomics and concerns over the security & privacy of genomic data restrain the growth of this market.

Moreover, the rising adoption of personalized medicines and gene therapies is expected to generate market growth opportunities. However, the shortage of skilled bioinformatics and genomics personnel and the commercialization and scaling of genomic technologies are major challenges for market stakeholders.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the global genomics market are Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Eppendorf SE (Germany), Myriad Genetics, Inc. (U.S.), Revvity, Inc. (Formerly PerkinElmer, Inc.) (U.S.), and BGI Genomics Co. Ltd (China).

Among all the offerings studied in this report, the consumables segment is projected to register the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to the increasing prevalence of genetic diseases, growing adoption of genetic testing, and recurring purchase of consumables over instruments. An increase in the prevalence of genetic disease cases has triggered the demand for genetic tests, which is driving the adoption of consumables. For instance, according to a report published by MJH Life Sciences (U.S.) in 2022, approximately 300,000 babies are born with sickle cell disease per year globally, and nearly 5% of the world's population is affected by the disease.

Among all the technologies studied in this report, in 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the genomics market. The increasing use of PCR in clinical diagnostics, technological advancements in PCR, collaborations for genomic research, and the use of PCR in these research studies are some of the factors contributing to the segment's largest share. Product launches further boost this segment's large market share. For instance, in March 2023, Bio-Rad Laboratories launched PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers to optimize PCR applications such as sequencing, cloning, and genotyping.

Among all the applications studied in this report, in 2024, the diagnostics segment is expected to account for the largest share of the genomics market. The use of genomics in oncology, newborn screening, and hepatitis testing is contributing to the largest share of the segment. Genomics is used in newborn screening, which are laboratory tests performed on newborn babies to identify known genetic diseases. Government agencies support newborn screening to reduce the incidence of genetic disorders among newborns through early detection, diagnosis, and intervention. For instance, in December 2022, the government of the U.K. invested more than USD 110.6 million (GBP 105 million) to speed up the rare disease diagnosis in newborns. Such initiatives play a vital role in driving the segment's largest share.

Among all the end users studied in this report, the pharmaceutical & biotechnology companies' segment is expected to record the highest CAGR during the forecast period. The highest CAGR of the segment is attributed to the increasing research & development by pharmaceutical & biotechnology companies, the rising utilization of genomics for research processes, and an increasing number of biotechnology companies. Moreover, the rising incidence of chronic diseases has accelerated the need to expedite drug development processes, further propelling the adoption of genomics among pharmaceutical companies.

An in-depth analysis of the geographical scenario of the global genomics market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the genomics market. North America is home to numerous renowned research institutions, universities, and organizations dedicated to genomics research; the region has made significant contributions to cancer genomics, with rising pharmaceutical R&D expenditure and the presence of key players. For instance, R&D spending by pharmaceutical companies in Canada for drug discovery has increased, driving the demand for genomics. For instance, in 2020, total R&D expenditure in Canada's pharmaceutical sector was estimated at between USD 1.8 billion and USD 2.4 billion, compared to USD 1.6 billion and USD 2.2 billion in 2019. Thus, the presence of research institutes, rising testing for genetic disorders, and increasing pharmaceutical R&D expenditure is supporting the largest regional share.

Scope of the Report:

Genomics Market Assessment-by Offering

  • Systems
  • Consumables
  • Software
  • Services

Genomics Market Assessment-by Technology

  • Polymerase Chain Reaction (PCR)
  • Sequencing
    • NGS
    • Other Sequencing Technologies
  • Nucleic Acid Extraction and Purification
  • Microarray
  • Other Technologies

Note: Other sequencing technologies include pyrosequencing, degradome sequencing, sanger sequencing, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing.

Note: Other technologies include cell counting, transfection, and gene editing.

Genomics Market Assessment-by Application

  • Diagnostics
  • Drug Discovery & Development
  • Life Sciences Research
    • Cancer Research
    • Stem Cell Research
    • Other Life Sciences Research
  • Other Applications

Note: Other life sciences research applications include cardiovascular research, osteoporosis, immunology, neurobiology, cellular and molecular biology, and diabetes

Note: Other applications include agriculture, forensics, and environmental.

Genomics Market Assessment-by End User

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Other End Users

Note: Other end users include food & beverage companies, agriculture companies, and forensics.

Genomics Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
  • 2.3. Market Sizing and Forecast
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Impact Analysis of Market Dynamics
      • 4.2.1.1. Rising Prevalence of Genetic Diseases and the Incorporation of Genomic Data in Clinical Workflows Driving Market Growth
      • 4.2.1.2. Concerns Over the Security & Privacy of Genomic Data Limiting the Adoption of Genomics Products
      • 4.2.1.3. Rising Adoption of Personalized Medicines and Gene Therapies
      • 4.2.1.4. Commercializing and Scaling Genomic Technologies Remain Major Challenges for Market Stakeholders
    • 4.2.2. Factor Analysis
  • 4.3. Technology Trends
  • 4.4. Genomics Market: Regulatory Analysis
    • 4.4.1. North America
      • 4.4.1.1. U.S.
      • 4.4.1.2. Canada
    • 4.4.2. Europe
      • 4.4.2.1. Shift From Pre-Approval to A Lifecycle Approach
      • 4.4.2.2. Classification Changes
      • 4.4.2.3. Stronger Supervision
      • 4.4.2.4. Clearer Rights and Responsibilities for Economic Operators
      • 4.4.2.5. Traceability/EUDAMED
      • 4.4.2.6. General Safety and Performance Requirements
      • 4.4.2.7. Performance Evaluation and Clinical Evidence
    • 4.4.3. Asia-Pacific
      • 4.4.3.1. China
      • 4.4.3.2. Japan
      • 4.4.3.3. India
    • 4.4.4. Latin America
    • 4.4.5. Middle East & Africa
    • 4.4.6. Guidelines and Regulations for Gene Therapy and Genome Editing
  • 4.5. Pricing Analysis
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Buyers
    • 4.6.2. Bargaining Power of Suppliers
    • 4.6.3. Threat of Substitutes
    • 4.6.4. Threat of New Entrants
    • 4.6.5. Degree of Competition

5. Genomics Market Assessment-by Offering

  • 5.1. Overview
  • 5.2. Consumables
  • 5.3. Instruments
  • 5.4. Software
  • 5.5. Services

6. Genomics Market Assessment-by Technology

  • 6.1. Overview
  • 6.2. Polymerase Chain Reaction (PCR)
  • 6.3. Sequencing
    • 6.3.1. Next-Generation Sequencing (NGS)
    • 6.3.2. Other Sequencing Technologies
  • 6.4. Nucleic Acid Extraction & Purification
  • 6.5. Microarray
  • 6.6. Other Technologies

7. Genomics Market Assessment-by Application

  • 7.1. Overview
  • 7.2. Diagnostics
  • 7.3. Drug Discovery & Development
  • 7.4. Life Sciences Research
    • 7.4.1. Cancer Research
    • 7.4.2. Stem Cell Research
    • 7.4.3. Other Life Sciences Research
  • 7.5. Other Applications

8. Genomics Market Assessment-by End User

  • 8.1. Overview
  • 8.2. Pharmaceutical & Biotechnology Companies
  • 8.3. Hospitals & Clinics
  • 8.4. Diagnostic Laboratories
  • 8.5. Contract Research Organizations (CROs)
  • 8.6. Academic & Research Institutes
  • 8.7. Other End Users

9. Genomics Market Assessment-by Geography

  • 9.1. Overview
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Rest Of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. India
    • 9.4.4. Rest Of Asia-Pacific
  • 9.5. Latin America
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America
  • 9.6. Middle East & Africa

10. Competition Analysis

  • 10.1. Introduction
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Share Analysis
    • 10.5.1. Thermo Fisher Scientific Inc. (U.S.)
    • 10.5.2. Illumina, Inc. (U.S.)
    • 10.5.3. Qiagen N.V. (Netherlands)

11. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)

  • 11.1. Thermo Fisher Scientific Inc.
  • 11.2. Illumina, Inc
  • 11.3. Qiagen N.V.
  • 11.4. Danaher Corporation
  • 11.5. Agilent Technologies, Inc.
  • 11.6. Bio-Rad Laboratories, Inc.
  • 11.7. Pacific Biosciences of California, Inc.
  • 11.8. Oxford Nanopore Technologies plc
  • 11.9. Eppendorf SE
  • 11.10. Myriad Genetics, Inc.
  • 11.11. Reevity, Inc. (Formerly PerkinElmer, Inc.)
  • 11.12. BGI Genomics Co.,Ltd.

(Note: SWOT Analysis of Top 5 Companies is Provided)

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports
  • Table 1 Regulatory Authorities Governing Genomic Products, by Country/Region
  • Table 2 Guidelines for Gene Therapy and Genome Editing, by Regulatory Body
  • Table 3 Pricing: Genomics Instruments
  • Table 4 Pricing: Genomics Consumables
  • Table 5 Average Selling Prices: Genomics Instruments
  • Table 6 Average Selling Prices: Genomics Consumables
  • Table 7 Global Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 8 Global Genomics Consumables Market, by Country/Region, 2022-2031 (USD Million)
  • Table 9 Global Genomics Instruments Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Genomics Software Market, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Global Genomics Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 13 Global Genomics Market for Polymerase Chain Reaction, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Genomics Market for Sequencing, by Type, 2022-2031 (USD Million)
  • Table 15 Global Genomics Market for Sequencing, by Country/Region, 2022-2031 (USD Million)
  • Table 16 Global Genomics Market for Next-Generation Sequencing, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Genomics Market for Other Sequencing Technologies, by Country/Region, 2022-2031 (USD Million)
  • Table 18 Global Genomics Market for Nucleic Acid Extraction and Purification, by Country/Region, 2022-2031 (USD Million)
  • Table 19 Global Genomics Market for Microarrays, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Genomics Market for Other Technologies, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Global Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 22 Global Genomics Market for Diagnostics, by Country/Region, 2022-2031 (USD Million)
  • Table 23 Global Genomics Market for Drug Discovery and Development, by Country/Region, 2022-2031 (USD Million)
  • Table 24 Global Genomics Market for Life Sciences Research, by Type, 2022-2031 (USD Million)
  • Table 25 Global Genomics Market for Life Sciences Research, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Number of New Cancer Cases, by Region, 2020 Vs. 2040 (In Million)
  • Table 27 Global Genomics Market for Cancer Research, by Country/Region, 2022-2031 (USD Million)
  • Table 28 Global Genomics Market for Stem Cell Research, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Genomics Market for Other Life Sciences Research, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Genomics Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 32 Global Genomics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Genomics Market for Hospitals & Clinics, by Country/Region, 2022-2031 (USD Million)
  • Table 34 Global Genomics Market for Diagnostic Laboratories, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Genomics Market for Contract Research Organizations (CROs) by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global Genomics Market for Academic & Research Institutes, by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global Genomics Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 38 Global Genomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 39 North America: Genomics Market, by Country, 2022-2031 (USD Million)
  • Table 40 North America: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 41 North America: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 42 North America: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 43 North America: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 44 North America: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 45 North America: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 46 U.S.: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 47 U.S.: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 48 U.S.: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 49 U.S.: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 50 U.S.: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 51 U.S.: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 52 Canada: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 53 Canada: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 54 Canada: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 55 Canada: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 56 Canada: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 57 Canada: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 58 Europe: Genomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 59 Europe: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 60 Europe: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 61 Europe: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 62 Europe: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 63 Europe: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 64 Europe: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 65 Germany: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 66 Germany: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 67 Germany: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 68 Germany: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 69 Germany: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 70 Germany: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 71 France: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 72 France: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 73 France: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 74 France: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 75 France: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 76 France: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 77 U.K.: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 78 U.K.: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 79 U.K.: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 80 U.K.: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 81 U.K.: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 82 U.K.: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 83 Italy: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 84 Italy: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 85 Italy: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 86 Italy: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 87 Italy: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 88 Italy: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 89 Spain: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 90 Spain: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 91 Spain: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 92 Spain: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 93 Spain: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 94 Spain: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 95 Rest of Europe: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 96 Rest of Europe: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 97 Rest of Europe: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 98 Rest of Europe: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 99 Rest of Europe: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 100 Rest of Europe: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 101 Asia-Pacific: Genomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 102 Asia-Pacific: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 103 Asia-Pacific: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 104 Asia-Pacific: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 105 Asia-Pacific: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 106 Asia-Pacific: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 107 Asia-Pacific: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 108 China: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 109 China: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 110 China: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 111 China: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 112 China: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 113 China: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 114 Japan: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 115 Japan: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 116 Japan: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 117 Japan: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 118 Japan: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 119 Japan: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 120 India: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 121 India: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 122 India: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 123 India: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 124 India: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 125 India: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 126 Rest of Asia-Pacific: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 127 Rest of Asia-Pacific: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 128 Rest of Asia-Pacific: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 129 Rest of Asia-Pacific: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 130 Rest of Asia-Pacific: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 131 Rest of Asia-Pacific: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 132 Latin America: Genomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 133 Latin America: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 134 Latin America: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 135 Latin America: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 136 Latin America: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 137 Latin America: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 138 Latin America: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 139 Brazil: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 140 Brazil: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 141 Brazil: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 142 Brazil: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 143 Brazil: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 144 Brazil: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 145 Mexico: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 146 Mexico: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 147 Mexico: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 148 Mexico: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 149 Mexico: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 150 Mexico: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 151 Rest of Latin America: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 152 Rest of Latin America: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 153 Rest of Latin America: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 154 Rest of Latin America: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 155 Rest of Latin America: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 156 Rest of Latin America: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 157 Middle East & Africa: Genomics Market, by Offering, 2022-2031 (USD Million)
  • Table 158 Middle East & Africa: Genomics Market, by Technology, 2022-2031 (USD Million)
  • Table 159 Middle East & Africa: Sequencing Market, by Type, 2022-2031 (USD Million)
  • Table 160 Middle East & Africa: Genomics Market, by Application, 2022-2031 (USD Million)
  • Table 161 Middle East & Africa: Genomics Market for Life Science Research, by Type, 2022-2031 (USD Million)
  • Table 162 Middle East & Africa: Genomics Market, by End User, 2022-2031 (USD Million)
  • Table 163 Recent Developments, by Company, 2020-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referred for This Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply Side & Dem and Side)
  • Figure 6 Market Sizing and Growth Forecast Approach
  • Figure 7 Global Genomics Market, by Offering, 2024 Vs. 2031 (USD Million)
  • Figure 8 Global Genomics Market, by Technology, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global Genomics Market, by Application, 2024 Vs. 2031 (USD Million)
  • Figure 10 Global Genomics Market, by End User, 2024 Vs. 2031 (USD Million)
  • Figure 11 Genomics Market, by Geography
  • Figure 12 Impact Analysis of Market Dynamics
  • Figure 13 Healthcare Expenditure as A Percentage of GDP in Major Countries, 2015 Vs. 2020
  • Figure 14 Global Pharmaceutical R&D Expenditure, 2012-2022 (USD Billion)
  • Figure 15 Estimated Number of New Cancer Cases, by Region, 2020 Vs. 2030 (in Thousand)
  • Figure 16 Percentage of FDA Approvals for Personalized Medicine, 2015-2021
  • Figure 17 USFDA Regulatory Pathways for Genomic Products
  • Figure 18 EU Regulatory Pathway IVDR 2017/746
  • Figure 19 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
  • Figure 20 Porter's Five Forces Analysis
  • Figure 21 Global Genomics Market, by Offering, 2024 Vs. 2031 (USD Million)
  • Figure 22 Global Genomics Market, by Technology, 2024 Vs. 2031 (USD Million)
  • Figure 23 Global Genomics Market, by Application, 2024 Vs. 2031 (USD Million)
  • Figure 24 Global Pharmaceutical R&D Expenditure, 2014-2026 (USD Billion)
  • Figure 25 Cancer Incidence Cases, 2020 Vs. 2040
  • Figure 26 Global Genomics Market, by End User, 2024 Vs. 2031 (USD Million)
  • Figure 27 Global Pharmaceutical R&D Spending, 2012-2026 (USD Billion)
  • Figure 28 Global Genomics Market Assessment, by Region, 2024 Vs. 2031 (USD Million)
  • Figure 29 North America: Genomics Market Snapshot
  • Figure 30 Europe: Genomics Market Snapshot
  • Figure 31 Asia-Pacific: Genomics Market Snapshot
  • Figure 32 Latin America: Genomics Market Snapshot
  • Figure 33 Key Growth Strategies Adopted by Leading Players, 2020-2023
  • Figure 34 Genomics Market: Competitive Benchmarking, by Offering
  • Figure 35 Genomics Market: Competitive Benchmarking, by Geography
  • Figure 36 Competitive Dashboard: Genomics Market
  • Figure 37 Global Genomics Market Share Analysis, by Key Players
  • Figure 38 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
  • Figure 39 Illumina, Inc.: Financial Overview (2022)
  • Figure 40 Qiagen N.V.: Financial Overview (2022)
  • Figure 41 Danaher Corporation: Financial Overview (2022)
  • Figure 42 Agilent Technologies, Inc.: Financial Overview (2023)
  • Figure 43 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
  • Figure 44 Pacific Biosciences of California, Inc.: Financial Overview (2022)
  • Figure 45 Oxford Nanopore Technologies plc.: Financial Overview (2022)
  • Figure 46 Eppendorf SE: Financial Overview (2022)
  • Figure 47 Myriad Genetics, Inc.: Financial Overview (2022)
  • Figure 48 PerkinElmer, Inc.: Financial Overview (2022)
  • Figure 49 BGI Genomics Co.,Ltd.: Financial Overview (2022)